Chapple C, Abrams P, eds. Male Lower Urinary Tract Symptoms (LUTS): An International Consultation on Male LUTS. Montreal, Canada: Societe Internationale d’Urologie; 2013.
Oishi K, Boyle P, Barry JM, et al. Epidemiology and natural history of benign prostatic hyperplasia. In: Denis L, et al, eds. Fourth International Consultation on BPH. Paris, July 1997. Plymouth, UK: Health Publications; 1998:25-59.
Roehrborn CG. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology and natural history. In: Walsh PC, et al, eds. Campbell’s Urology. 8th ed. Philadelphia, PA: WB Saunders Co; 2012:2570-2610.
Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol. 2004;6:S3-S10.
Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008;20:S11-S18.
McKinlay JB, Link CL. Measuring the urologic iceberg: design and implementation of the Boston Area Community Health (BACH) Survey. Eur Urol. 2007;52:389-396. Abstract
Barry MJ, Fowler FJ Jr, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. Measurement Committee of the American Urological Association. J Urol. 1992;148:1549-1557. Abstract
Roehrborn CG, Girman CJ, Rhodes T, et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology. 1997;49:548-557. Abstract
Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-134. Abstract
Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53:581-589. Abstract
Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology. 1999;54:662-669. Abstract
Lee AJ, Russell EB, Garraway WM, Prescott RJ. Three-year follow-up of a community-based cohort of men with untreated benign prostatic hyperplasia. Eur Urol. 1996;30:11-17. Abstract
Bosch JL, Weiss JP. The prevalence and causes of nocturia. J Urol. 2010;184:440-446 . Abstract
Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008;53:1228-1235. Abstract
Girman CJ, Panser LA, Chute CG, et al. Natural history of prostatism: urinary flow rates in a community-based study. J Urol. 1993;150:887-892. Abstract
Abrams P, et al. In: Chatelain C et al, eds. Benign Prostatic Hyperplasia. Plymouth, UK: Health Publication Ltd; 2001:227-281.
Crawford ED, Wilson SS, McConnell JD, et al; MTOPS RESEARCH Group. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175:1422-1426. Abstract
Griffiths D, Höfner K, van Mastrigt R, Rollema HJ, Spångberg A, Gleason D. Standardization of terminology of lower urinary tract function: pressure-flow studies of voiding, urethral resistance, and urethral obstruction. International Continence Society Subcommittee on Standardization of Terminology of Pressure-Flow Studies. Neurourol Urodyn. 1997;16:1-18. Abstract
Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M. Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994;113:723-728. Abstract
Lepor H. Medical treatment of benign prostatic hyperplasia. Rev Urol. 2011;13:20-33. Abstract
Schwinn DA, Michelotti GA. alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000;85:6-11. Abstract
Yoo TK, Cho HJ. Benign prostatic hyperplasia: from bench to clinic. Korean J Urol. 2012;53:139-148. Abstract
Yuan J, Liu Y, Yang Z, Qin X, Yang K, Mao C. The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. Curr Med Res Opin. 2013;29:279-287. Abstract
Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol. 2012;2012:530121.
Gravas S, Oelke M. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol. 2010;28:9-15. Abstract
Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5a-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8:872-884. Abstract
Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46-53. Abstract
Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350:786-799. Abstract
Sellers DJ, Yamanishi T, Chapple CR, Couldwell C, Yasuda K, Chess-Williams R. M3 muscarinic receptors but not M2 mediate contraction of the porcine detrusor muscle in vitro. J Auton Pharmacol. 2000;20:171-176. Abstract
Giuliano F, Ückert S, Maggi M, Birder L, Kissel J, Viktrup L. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2013;63:506-516. Abstract
Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008;15:193-199. Abstract
Kaplan SA. Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function. Urology. 2004;63:428-434. Abstract
Nasu K, Moriyama N, Kawabe K, et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol. 1996;119:797-803. Abstract
Murata S, Taniguchi T, Takahashi M, Okada K, Akiyama K, Muramatsu I. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol. 2000;164:578-583. Abstract
Carbone DJ Jr, Hodges S. Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impotence Res. 2003;15:299-306.
Stafford-Smith M, Bartz R, Wilson K, Baraniuk JN, Schwinn DA. Alpha-adrenergic mRNA subtype expression in the human nasal turbinate. Can J Anesth. 2007;54:549-555. Abstract
Townsend SA, Jung AS, Hoe YS, et al. Critical role for the alpha-1B adrenergic receptor at the sympathetic neuroeffector junction. Hypertension. 2004;44:776-782. Abstract
McConnell JD, Roehrborn CG, Bautista OM, et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398. Abstract
Roehrborn CG, Siami P, Barkin J, et al; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131. Abstract
Roehrborn CG, Nickel JC, Andriole GL, et al. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Urology. 2011;78:641-646. Abstract
Roehrborn CG, Barkin J, Siami P, et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int. 2011;107:946-954. Abstract
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306-1315. Abstract
Abrams P, Cardozo L, Fall M, et al; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37-49. Abstract
Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004;94:817-820. Abstract
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61. Abstract
McVary KT, et al. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int. 2006;97(suppl 2):23-28. Abstract
Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30:292-301. Abstract
Köhler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol. 2009;55:38-48. Abstract
Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology. 2010;75:1452-1458. Abstract
Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61:917-925. Abstract
Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61:994-1003. Abstract

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Claus G. Roehrborn, MD

Professor and Chairman, Department of Urology, University of Texas Southwestern Medical Center at Dallas; Department of Urology, University Hospitals of UT Southwestern, Parkland Memorial Hospital, Dallas, Texas

Disclosures

Disclosure: Claus G. Roehrborn, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: GlaxoSmithKline; Lilly
Received grants for clinical research from: GlaxoSmithKline; Lilly

Dr Roehrborn does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Roehrborn does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist

Kevin T. McVary, MD, FACS

Professor and Chairman, Department of Urology, Southern Illinois University School of Medicine, Springfield, Illinois

Disclosures

Disclosure: Kevin T. McVary, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allergan, Inc.; Lilly; NeoTract; NxThera; Watson Pharmaceuticals, Inc.
Served as a speaker or a member of a speakers bureau for: GlaxoSmithKline
Received honorarium from: Allergan, Inc.; Lilly; NeoTract; NxThera; Watson Pharmaceuticals, Inc.

Dr McVary does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr McVary does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Margaret McLaughlin, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Margaret McLaughlin, PhD, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME

Initial Evaluation and Treatment of Male Lower Urinary Tract Symptoms

Authors: Claus G. Roehrborn, MD; Kevin T. McVary, MD
CME Released: 6/26/2014
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 6/26/2015

Start Activity

Target Audience and Goal Statement

This activity is intended for physicians, nurses, nurse practitioners, and physician assistants practicing in primary care, urology, internal medicine, family practice, and/or who have the opportunity to address men’s healthcare concerns.

The goal of this activity is to provide an update of treatment of male lower urinary tract symptoms (LUTS).

Upon completion of this activity, participants will be able to:

Diagnose and determine initial treatment for patients with LUTS, including watchful waiting, lifestyle changes, pharmacologic therapy, and referral to a specialist for more complicated LUTS
Formulate a plan for monitoring and addressing adverse treatment effects for patients with LUTS based on the pharmacology of the medications

Disclosures

Moderator

Claus G. Roehrborn, MD

Professor and Chairman, Department of Urology, University of Texas Southwestern Medical Center at Dallas; Department of Urology, University Hospitals of UT Southwestern, Parkland Memorial Hospital, Dallas, Texas

Disclosures

Disclosure: Claus G. Roehrborn, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: GlaxoSmithKline; Lilly
Received grants for clinical research from: GlaxoSmithKline; Lilly

Dr Roehrborn does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Roehrborn does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist

Kevin T. McVary, MD, FACS

Professor and Chairman, Department of Urology, Southern Illinois University School of Medicine, Springfield, Illinois

Disclosures

Disclosure: Kevin T. McVary, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allergan, Inc.; Lilly; NeoTract; NxThera; Watson Pharmaceuticals, Inc.
Served as a speaker or a member of a speakers bureau for: GlaxoSmithKline
Received honorarium from: Allergan, Inc.; Lilly; NeoTract; NxThera; Watson Pharmaceuticals, Inc.

Dr McVary does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr McVary does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Margaret McLaughlin, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Margaret McLaughlin, PhD, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Urology

CME

Initial Evaluation and Treatment of Male Lower Urinary Tract Symptoms

Authors: Claus G. Roehrborn, MD; Kevin T. McVary, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 6/26/2014

Valid for credit through: 6/26/2015

processing....

This feature requires the newest version of Flash. You can download it here.

CME Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

Claus G. Roehrborn, MD

Panelist

Kevin T. McVary, MD, FACS

Editor

Margaret McLaughlin, PhD

CME Reviewer(s)

Nafeez Zawahir, MD

Peer Reviewer

CME

Initial Evaluation and Treatment of Male Lower Urinary Tract Symptoms

Target Audience and Goal Statement

Disclosures

Moderator

Claus G. Roehrborn, MD

Panelist

Kevin T. McVary, MD, FACS

Editor

Margaret McLaughlin, PhD

CME Reviewer(s)

Nafeez Zawahir, MD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Initial Evaluation and Treatment of Male Lower Urinary Tract Symptoms